{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:51:00Z","timestamp":1789779060523,"version":"4.0.1"},"reference-count":54,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"unspecified","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,1,16]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The rapidly advancing field of cancer therapy has sparked growing interest in the potential synergy between anticoagulation and immune checkpoint inhibitor (ICI) therapy. Recent research highlights that anticoagulants, traditionally used for thromboprophylaxis and managing thromboembolic events, may also exhibit immunomodulatory properties. These properties can influence the tumor microenvironment by promoting immune cell infiltration, enhancing antitumor immune responses, and potentially reducing metastasis. This emerging evidence underscores the complex interplay between coagulation pathways and immune regulation, paving the way for further exploration of the clinical benefits of combining anticoagulation with ICI therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted to synthesize the current evidence on the interplay between anticoagulation and ICI. Relevant studies examining their mechanisms of action, clinical outcomes, and potential interactions were identified and analyzed. Comprehensive database searches were performed to ensure a thorough and inclusive review of the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Preclinical studies consistently show that combining ICIs with anticoagulants can enhance cancer treatment by inhibiting tumor growth and metastasis. In particular, low molecular weight heparin, oral factor Xa (FXa) inhibitors, and platelet inhibitors have demonstrated synergistic effects with ICI. However, these findings have not been consistently replicated in clinical settings. While two retrospective studies reported no significant impact of anticoagulants on ICI efficacy, one retrospective study found improved outcomes in advanced melanoma patients treated with ICI and FXa inhibitors. Additionally, another retrospective study revealed a significant association between platelet aggregation inhibition and extended progression-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our literature review underscores the intricate relationship between anticoagulation and ICIs in cancer therapy. Future studies should prioritize exploring the interactions between ICI, FXa inhibitors, and antiplatelet agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013879","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T14:56:23Z","timestamp":1770216983000},"page":"e013879","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Synergistic effects of anticoagulants and platelet aggregation inhibitors with immune checkpoint inhibitors in cancer therapy: a comprehensive review of preclinical and clinical evidence"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2073-3909","authenticated-orcid":false,"given":"Julian","family":"K\u00f6tt","sequence":"first","affiliation":[{"name":"Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Fleur Hiege Center of Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Matthes","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Fleur Hiege Center of Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T","family":"Bauer","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Fleur Hiege Center of Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Fleur Hiege Center of Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Zell","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Fleur Hiege Center of Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-9511","authenticated-orcid":false,"given":"Daniel J","family":"Smit","sequence":"additional","affiliation":[{"name":"Fleur Hiege Center of Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W","family":"Schneider","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Fleur Hiege Center of Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7090-9584","authenticated-orcid":false,"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Fleur Hiege Center of Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"2026062607451384000_14.2.e013879.1","article-title":"Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics","volume":"15","author":"Abaza","year":"2023","journal-title":"Cureus"},{"key":"2026062607451384000_14.2.e013879.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6"},{"key":"2026062607451384000_14.2.e013879.3","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.434"},{"key":"2026062607451384000_14.2.e013879.4","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247"},{"key":"2026062607451384000_14.2.e013879.5","first-page":"103","article-title":"Immune Checkpoint Inhibitors in the Treatment of Cancer","volume":"17","author":"Zam","year":"2022","journal-title":"CRCEP"},{"key":"2026062607451384000_14.2.e013879.6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12032-023-02114-6","article-title":"Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events","volume":"40","author":"Meybodi","year":"2023","journal-title":"Med Oncol"},{"key":"2026062607451384000_14.2.e013879.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X"},{"key":"2026062607451384000_14.2.e013879.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.017"},{"key":"2026062607451384000_14.2.e013879.9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?","volume":"39","author":"Fares","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026062607451384000_14.2.e013879.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.03.012"},{"key":"2026062607451384000_14.2.e013879.11","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S2589-7500(23)00082-1","article-title":"Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study","volume":"5","author":"Saad","year":"2023","journal-title":"Lancet Digit Health"},{"key":"2026062607451384000_14.2.e013879.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229"},{"key":"2026062607451384000_14.2.e013879.13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081103","article-title":"Coagulation Factor Xa Promotes Solid Tumor Growth, Experimental Metastasis and Endothelial Cell Activation","volume":"11","author":"Arce","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026062607451384000_14.2.e013879.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.002"},{"key":"2026062607451384000_14.2.e013879.15","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw8405","article-title":"Myeloid cell-synthesized coagulation factor X dampens antitumor immunity","volume":"4","author":"Graf","year":"2019","journal-title":"Sci Immunol"},{"key":"2026062607451384000_14.2.e013879.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005710"},{"key":"2026062607451384000_14.2.e013879.17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.trecan.2021.12.008","article-title":"Coagulome and the tumor microenvironment: an actionable interplay","volume":"8","author":"Galmiche","year":"2022","journal-title":"Trends Cancer"},{"key":"2026062607451384000_14.2.e013879.18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.1.22"},{"key":"2026062607451384000_14.2.e013879.19","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S0049-3848(10)70017-7","article-title":"Antimetastatic activities of heparins and modified heparins. Experimental evidence","volume":"125 Suppl 2","author":"Borsig","year":"2010","journal-title":"Thromb Res"},{"key":"2026062607451384000_14.2.e013879.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2003.11.007"},{"key":"2026062607451384000_14.2.e013879.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-021-02712-w","article-title":"Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients","volume":"19","author":"Johannet","year":"2021","journal-title":"J Transl Med"},{"key":"2026062607451384000_14.2.e013879.22","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1158\/1078-0432.CCR-22-2757","article-title":"Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates","volume":"29","author":"Wei","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026062607451384000_14.2.e013879.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012213432504"},{"key":"2026062607451384000_14.2.e013879.24","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-013-0230-0"},{"key":"2026062607451384000_14.2.e013879.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-460147"},{"key":"2026062607451384000_14.2.e013879.26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001719","article-title":"Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival","volume":"9","author":"Sussman","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026062607451384000_14.2.e013879.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007338"},{"key":"2026062607451384000_14.2.e013879.28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184606","article-title":"Thrombotic Complications Associated with Immune Checkpoint Inhibitors","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026062607451384000_14.2.e013879.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007878"},{"key":"2026062607451384000_14.2.e013879.30","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03850-y","article-title":"Interdependence of coagulation with immunotherapy and BRAF\/MEK inhibitor therapy: results from a prospective study","volume":"74","author":"Beckmann","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2026062607451384000_14.2.e013879.31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3324\/haematol.2022.281315","article-title":"Von Willebrand factor in the plasma and in the tumor tissue predicts cancer-associated thrombosis and mortality","volume":"108","author":"Karampinis","year":"2022","journal-title":"Haematol"},{"key":"2026062607451384000_14.2.e013879.32","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026062607451384000_14.2.e013879.33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007080","article-title":"Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer","volume":"11","author":"Quan","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026062607451384000_14.2.e013879.34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002332","article-title":"Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia","volume":"9","author":"Choi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026062607451384000_14.2.e013879.35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay4860","article-title":"Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-\u03b2","volume":"12","author":"Metelli","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026062607451384000_14.2.e013879.36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-065995"},{"key":"2026062607451384000_14.2.e013879.37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-101048"},{"key":"2026062607451384000_14.2.e013879.38","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164528","article-title":"Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma","volume":"133","author":"Lin","year":"2023","journal-title":"J Clin Invest"},{"key":"2026062607451384000_14.2.e013879.39","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai7911","article-title":"Platelets subvert T cell immunity against cancer via GARP-TGF\u03b2 axis","volume":"2","author":"Rachidi","year":"2017","journal-title":"Sci Immunol"},{"key":"2026062607451384000_14.2.e013879.40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595686"},{"key":"2026062607451384000_14.2.e013879.41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006456","article-title":"Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors","volume":"11","author":"Stadler","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026062607451384000_14.2.e013879.42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205103","article-title":"Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors-A Retrospective, Real-World Cohort Study","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026062607451384000_14.2.e013879.43","doi-asserted-by":"crossref","first-page":"115159","DOI":"10.1016\/j.ejca.2024.115159","article-title":"Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg","volume":"214","author":"K\u00f6tt","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026062607451384000_14.2.e013879.44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.21037\/apm.2017.11.01","article-title":"Bleeding in cancer patients and its treatment: a review","volume":"7","author":"Johnstone","year":"2018","journal-title":"Ann Palliat Med"},{"key":"2026062607451384000_14.2.e013879.45","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e328353efd8"},{"key":"2026062607451384000_14.2.e013879.46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0901944106"},{"key":"2026062607451384000_14.2.e013879.47","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41586-025-08626-7","article-title":"Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity","volume":"640","author":"Yang","year":"2025","journal-title":"Nature New Biol"},{"key":"2026062607451384000_14.2.e013879.48","doi-asserted-by":"publisher","DOI":"10.1001\/.458"},{"key":"2026062607451384000_14.2.e013879.49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010067","article-title":"Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients","volume":"12","author":"Nichetti","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026062607451384000_14.2.e013879.50","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11832"},{"key":"2026062607451384000_14.2.e013879.51","doi-asserted-by":"crossref","first-page":"30606","DOI":"10.1038\/s41598-025-16236-6","article-title":"Concomitant anticoagulants and the survival of cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"15","author":"Xiong","year":"2025","journal-title":"Sci Rep"},{"key":"2026062607451384000_14.2.e013879.52","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamaoncol.2024.2503","article-title":"Aspirin Use and Incidence of Colorectal Cancer According to Lifestyle Risk","volume":"10","author":"Sikavi","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026062607451384000_14.2.e013879.53","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1182\/bloodadvances.2022008086","article-title":"ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis","volume":"6","author":"Giustozzi","year":"2022","journal-title":"Blood Adv"},{"key":"2026062607451384000_14.2.e013879.54","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0274"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013879","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:45:30Z","timestamp":1782485130000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,4]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/jitc-2025-013879"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013879","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}